menu

CME: Seeing Eye to Eye: Case Series on Treatment Strategies for Diabetic Retinopathy Mod/Severe NPDR

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Seeing Eye to Eye: Case Series on Treatment Strategies for Diabetic Retinopathy Mod/Severe NPDR

Program Information
Recommended
Seeing Eye to Eye: Case Series on Treatment Strategies for Diabetic Retinopathy Mod/Severe NPDR
RestartResume
How can you integrate new clinical trial data on the use of anti-VEGF inhibitors for the management of NPDR into clinical practice?

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The treatment of nonproliferative diabetic retinopathy (NPDR) in the presence of diabetic macular edema is well established, but what about those patients with severe NPDR who do not have diabetic macular edema? To find out, Dr. Diana Do sits down with Dr. Peter Kaiser and Dr. Charles Wykoff, who review recent clinical trial data from the PANORAMA study and its treatment implications.

    Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host 

    Diana V. Do, MD
    Professor of Ophthalmology and Vice Chair for Clinical Affairs
    Byers Eye Institute
    Stanford University School of Medicine
    Palo Alto, CA

    Research Support: BioTime, Genentech, Regeneron, Santen
    Scientific Advisory Board: Allergan, Clearside, Genentech, Kodiak, Regeneron

    Faculty:  

    Peter K. Kaiser, MD
    Professor of Ophthalmology
    Cleveland Clinic Lerner College of Medicine
    Cleveland, OH

    Consulting Fees: Aerie, Aerpio, Alcon, Allegro, Allergan, Annexon Biosciences, Bayer, Bausch and Lomb, Biogen Idec, Boerenger Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, Eyevensys, Formycon/BioEq GmbH, Galecto Biotech, Galimedix, Glaukos, Hospira, iRenix, jCyte, Kala Pharmaceuticals, Kanghong, Kodiak, NGM Biopharmaceuticals, Inc., Novartis, Ocugenix, Omeros, Opthea, Oxurion (Thrombogenics), Regeneron, RegenexBio, Retinal Sciences, Roivant, Santen, SciFluor, Shire, Spark, Stealth Biotherapeutics, Verena (Digisight)

    Charles Wykoff, MD, PhD
    Associate Professor of Clinical Ophthalmology, Institute for Academic Medicine
    Associate Clinical Member, Research Institute
    Houston Methodist
    Weill Cornell Medical College
    Houston, TX 

    Consulting Fees: Adverum, Aerpio, Alimera, Allegro, Allergan, Apellis, Bayer, Clearside Biomedical, DORC, EyePoint, Fosun, Genentech, Kodiak, Novartis, ONL Therapeutics, Ophthotech, Polyphotonix, RecensMedical, Regeneron, Regenxbio, Roche, Santen, Takeda
    Commercial Interest Speakers Bureau: Regeneron
    Research Grant Support: Adverum, Aerpio, Allergan, Apellis, Chengdu, Kanghong, Clearside Biomedical, Genentech, Iveric Bio (formerly Ophthotech), Kodiak, Neurotech, Novartis, Opthea, RecensMedical, Regeneron, Regenxbio, Roche, Samsung, Santen

    Reviewers/Content Planners/Authors:

    • Rob Braun has nothing to disclose.
    • Emily Chew, MD has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose.
    • Robert S. Schneider, MSW has nothing to disclose.
    • Stephanie Wenick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Integrate recent clinical trial data surrounding the use of anti-VEGF inhibitors for the management of nonproliferative DR into clinical practice
  • Target Audience

    This activity is designed to meet the educational needs of retina specialists and other eye health professionals.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and the National Eye Institute of the National Institutes of Health, of the U.S. Department of Health and Human Services. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

    This activity is provided in partnership with the National Eye Institute, of the National Institutes of Health, of the US Department of Health and Human Services. The National Eye Health Education Program of the NEI is acknowledged for its important contributions to this initiative.

  • Commercial Support

    This activity is supported by an independent educational grant from Regeneron Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/6/19

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.